{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.5958","statisticalMethod":"Stratified Log-rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.34","upperLimit":"11.73","value":"9.82"},{"groupId":"OG001","lowerLimit":"8.11","upperLimit":"11.24","value":"9.40"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"220"}],"units":"Participants"}],"description":"OS was defined as the time from randomization to death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Encorafenib + binimetinib + cetuximab. Encorafenib: Orally, once daily. Binimetinib: Orally, twice daily. Cetuximab: Standard of care.","id":"OG000","title":"Phase 3: Triplet Arm"},{"description":"Encorafenib + cetuximab. Encorafenib: Orally, once daily. Cetuximab: Standard of care.","id":"OG001","title":"Phase 3: Doublet Arm"}],"paramType":"MEDIAN","populationDescription":"The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 participants.","reportingStatus":"POSTED","timeFrame":"From randomization to death due to any cause until 204 deaths were observed (maximum treatment exposure of 89.7 weeks for doublet arm and 89.1 weeks for triplet arm)","title":"(Phase 3) Overall Survival (OS) in Triplet Arm vs. Doublet Arm","type":"SECONDARY","unitOfMeasure":"Months"}